Abbott expands vascular operations in Ireland for drug-eluting stent

By E. Janene Geiss

Philadelphia, Sept. 12 - Abbott Laboratories said Tuesday that it continued to expand its Abbott Vascular sites in Ireland, which includes the opening of its new 180,000-square-foot state-of-the-art manufacturing facility in Clonmel.

The company also unveiled architectural drawings of an additional 70,000-square-foot administration, warehouse and logistics facility to accommodate future growth in Clonmel, according to a news release from the Abbott Park, Ill., pharmaceutical company.

The expansion plays an important role in the company's drug-eluting stent manufacturing operations.

Abbott said it plans to initiate next month the European launch of its first drug-eluting stent, the Xience V Everolimus eluting coronary stent system. The stent received CE Mark approval earlier this year. Positive six-month results for the stent system were reported recently at the World Congress of Cardiology conference in Barcelona, Spain.

Abbott is awaiting CE Mark approval for its ZoMaxx drug-eluting coronary stent system. Both the Xience V and ZoMaxx drug-eluting stents are investigational in the United States.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.